February 25, 2009 - The Centre Oscar Lambret in Lille, France, has begun treating cancer patients using the TomoTherapy Hi·Art treatment system, which is the first of two Hi·Art treatment systems that Centre Oscar Lambret has ordered.

“The choice for TomoTherapy was guided by the need to offer IMRT (intensity-modulated radiation therapy) treatment to our patients. Approximately 3,000 treatments are provided each year, with a high incidence of head and neck and pelvic or cervix tumors, so the choice was obvious. Furthermore, the IMRT delivered by TomoTherapy was the best option for us in order to implement rapidly a modern and very efficient technique. The need to distribute very accurate dose and reduce normal tissues morbidity has been a key criteria in our choice,” said Eric Lartigau, M.D., Ph.D., professor of Radiation Oncology at the University of Lille and chairman of the Radiation Oncology Department, director of research and co-operations at the Centre Oscar Lambret.

The second system will be installed later in 2009.

For more information: www.centreoscarlambret.fr


Related Content

News | Intensity Modulated Radiation Therapy (IMRT)

March 14, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time March 14, 2022
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

October 22, 2021 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

Time October 22, 2021
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

October 27, 2020 — A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical ...

Time October 27, 2020
arrow
News | Radiation Therapy

June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...

Time June 10, 2020
arrow
News | Radiation Therapy

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time April 16, 2020
arrow
News | Proton Therapy

January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down ...

Time January 29, 2020
arrow
Technology | Image Guided Radiation Therapy (IGRT)

Accuray announced the launch of its Synchrony motion tracking and correction technology to be used with the Radixact System. This new feature adds intrafraction motion synchronization capabilities to the Radixact System, enabling real-time tracking, visualization and correction for tumor motion during treatment, with the goal of improving dose accuracy and treatment times compared to conventional radiation therapy systems. The Radixact System with Synchrony will be unveiled at the European Society for Radiotherapy & Oncology (ESTRO) meeting, April 26-30 in Milan, Italy.

Time April 24, 2019
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with hypofractionated intensity modulated radiation therapy (HIMRT) yields equivalent disease outcomes compared with conventional intensity modulated radiation (CIMRT). It is the largest randomized single-institution study with the longest follow-up period on this topic to date.

Time October 31, 2018
arrow
News | Proton Therapy

IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton therapy solution in Japan. The first installation took place at the Hokkaido Ohno Memorial Hospital in Sapporo and the other at the Narita Memorial Proton Center in Toyohashi. Both installations were successful, according to the company, as the Hokkaido Ohno Memorial Hospital installation took less than 12 months and the Narita Memorial Proton Center installation took less than 11 months.

Time July 30, 2018
arrow
News | Radiation Therapy

March 26, 2018 — Radiotherapy treatment to part of the breast or a reduced dose to the whole breast yields fewer ...

Time March 26, 2018
arrow
Subscribe Now